SBI Healthcare Opportunities Fund
Institution · data to Jun 2026
Disclosed value
₹1,652 Cr
Jun 2026 closes
At current prices
…
Current holdings
4
Tracked since
Jun 2018
Portfolio value over time
Sum of disclosed holdings across all combined entities, valued at each quarter's closing price.
Current holdings (Jun 2026)
| Company | Holding | QoQ | Value |
|---|---|---|---|
| Jupiter Life Line Hospitals Ltd | 7.77% | flat | ₹742 Cr |
| Acutaas Chemicals Ltd | 2.35% | 0.43 | ₹711 Cr |
| Sudeep Pharma Ltd | 1.20% | flat | ₹118 Cr |
| Nephrocare Health Services Ltd | 1.19% | flat | ₹80 Cr |
Portfolio Summary
Jun 2026As of Jun 2026, SBI Healthcare Opportunities Fund — an institution tracked through public shareholding filings — disclosed 4 holdings in Indian listed companies worth ₹1,652 crore. The same holdings-at-filing-value basis put it at ₹1,105 crore in Mar 2026 (+49.5%). Solomo carries these filings back to Jun 2018.
Largest disclosed positions in Jun 2026: Jupiter Life Line Hospitals Ltd (JLHL — 7.77% of the company, ₹742 crore); Acutaas Chemicals Ltd (ACUTAAS — 2.35% of the company, ₹711 crore); Sudeep Pharma Ltd (SUDEEPPHRM — 1.20% of the company, ₹118 crore); Nephrocare Health Services Ltd (NEPHROPLUS — 1.19% of the company, ₹80 crore).
Changes in the Jun 2026 filings: Stake raised in Acutaas Chemicals Ltd (+0.43 pp).
| Quarter | Disclosed value | Change |
|---|---|---|
| Jun 2026 | ₹1,652 Cr | +49.5% |
| Mar 2026 | ₹1,105 Cr | +30.6% |
| Dec 2025 | ₹846 Cr | −7.6% |
| Sep 2025 | ₹916 Cr | −37.4% |
| Jun 2025 | ₹1,464 Cr | −30.1% |
| Mar 2025 | ₹2,094 Cr | −2.5% |
| Dec 2024 | ₹2,148 Cr | +179.3% |
| Sep 2024 | ₹769 Cr | +6.7% |